Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Diminished amplification of SARS-CoV-2 ORF1ab in a commercial dual-target qRT-PCR diagnostic assay

Stephanie Popping a,*, Richard Molenkamp a, Joachim D. Weigel b, Pim G.N.J. Mutsaers c, Jolanda C. Voermans a, Sander van Boheemen a, Marc C. Shamier a, Reina S. Sikkema a, David F. Nieuwenhuijse a, Bas B. Oude Munnink a, Marion P.G. Koopmans a, Jeroen J. A. van Kampen a,*,

a Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands
b Department of Intensive Care, Erasmus MC, Rotterdam, the Netherlands
c Department of Hematology, Erasmus MC, Rotterdam, the Netherlands

ARTICLE INFO

Keywords:
SARS-CoV-2
PCR amplification
Molecular diagnostics SARS-CoV-2
ORF1ab mutations
Cobas
Dual-target assay

ABSTRACT

Here we describe a SARS-CoV-2 variant with diminished amplification of the ORF1ab target in the Cobas® dual-target SARS-CoV-2 assay resulting in a discrepancy of Ct-values (Ct-value 20.7 for the E-gene and Ct-value 30.2 for ORF1ab). Five unique nucleotide mutations were identified in ORF1ab: C11450A (nsp10) C14178T (RdRp), G15006T (RdRp), G18394T (Hel), and G20995T (Hel). This case highlights the importance of surveillance of genomic regions used in molecular diagnostics and the importance of the public release of target regions used to update commercial and in-house developed SARS-CoV-2 PCR tests. This work underpins the importance of using dual-targets in molecular diagnostic assays to limit the change of false-negative results due to primer and/or probe mismatches.

1. Short communications

SARS-CoV-2 is highly contagious and has rapidly evolved into a global pandemic overburdening healthcare systems worldwide. Prompt molecular detection of SARS-CoV-2 is crucial to identify and isolate infected individuals thus preventing further SARS-CoV-2 transmission. The early availability of the SARS-CoV-2 genome sequence led to the fast development of in-house PCR protocols followed by several commercially available qRT-PCR assays such as, the widely used Cobas® dual-target SARS-CoV-2 assay (Corman et al., 2020; Iglói et al., 2020).

SARS-CoV-2 has an estimated ~1 × 10⁻³ substitutions per nucleotide position per year, which is comparable to SARS-CoV-1 and other coronaviruses (Duchene et al., 2020). Viral mutations in the primer or probe binding regions of SARS-CoV-2 could lead to mismatches, resulting in false negative PCR results. As an example, the B.1.1.7 (alpha) variant had deletions at positions 69 and 70 which causes failure of the S-gene target used in the Thermofisher® diagnostic assay (Public Health England, 2020). Furthermore, SARS-CoV-2 variants with mutations at position 26340 in the E-gene led to target failure in one of the targets of the Cobas® dual-target assay (Artesi et al., 2020). Reporting such findings is of utmost importance to update commercial and in-house developed SARS-CoV-2 PCR tests. Here we report a patient infected with a SARS-CoV-2 variant that showed diminished amplification of the ORF1ab target of the Cobas® dual-target SARS-CoV-2 assay.

A 55-year-old woman with a recently diagnosed aggressive B-cell non-Hodgkin lymphoma (double-hit lymphoma, DHL) and pulmonary embolism (PE) was presented to the emergency department with periodic episodes of non-neutropenic fever and progressive pain in her right leg. Admission vitals were not alarming except her admission labs showed a platelet count of 48.000/μL, a leucocytosis of 25.000/μL, and a haemoglobin concentration of 4.9 mmol/L, related to intensive immunochemotherapy (DA-EPOCH-R) and granulocyte colony stimulating factor (G-CSF) given two weeks before the index hospitalization. The next day, the patient was found mottled, unresponsive, and profound hypotensive. She was immediately transferred to the intensive care unit (ICU). She was intubated, mechanically ventilated, and temporarily started on norepinephrine to control persistent hypotension to some extent. An abdominal computed tomography (CT) scan showed massive bleeding in the iliopsoas muscle, possibly multifactorial, a combination of therapeutic nadroparin, thrombocytopenia and direct lymphoma...
infiltration in her right gluteal muscle. Her hemodynamic condition was treated with fluid resuscitation including blood- and platelet transfusion. Haemodynamic stability could not be achieved until endovascular embolization was performed.

The course of her admission was further characterized in particular by respiratory distress with SARS-CoV-2 pneumonia. At admission to the emergency department, the patient tested positive for SARS-CoV-2 using the Cobas® SARS-CoV-2 test. A lung computed tomography (CT) scan revealed the typical signs of SARS-CoV-2 pneumonia, such as bilateral ground-glass opacities and consolidation. However, despite the application of lung-protective ventilation and additional therapies including neuromuscular blockade and high dose corticosteroids, acute respiratory distress syndrome (ARDS) with refractory hypoxaemia persisted. Prone positioning (PP) was applied to improve oxygenation (PaO2/FiO2 ratio) by recruitment of atelectasis (collapsed lung parenchyma) in dorsal lung parts creating more lung homogeneity and increased total aerated lung volume. PP was initially effective by rapidly improving blood oxygenation, but the situation promptly deteriorated probably due to ongoing massive alveolar damage. At an interval as required by our daily clinical practice, detecting SARS-CoV-2 RNA in oropharyngeal swab and lower respiratory tract samples, and serum-IgG 

**Table 1** Virological investigations and CT-values.

| Days from admission | 1 | 3 | 10 | 14 | 16 | 17 | 18 | 19 | 20 | 21 | 22 |
|---------------------|---|---|----|----|----|----|----|----|----|----|----|
| Nasopharyngeal swab  |   |   |    |    |    |    |    |    |    |    |    |
| Cobas® E-gene       | 21.2 | 19.2 | 20.7 | 19 | 21 | 21.3 | 21.1 | 23.1 | 23.1 | 20.6 | 20.3 |
| Cobas® ORF1ab       | 27.4 | 28.4 | 30.2* | 29.4** | 29 | 28.4 | 27.2 | 29.5 | 29.8 | 28.9 | 30.2 |
| In-house PCR E-gene | 19.4 | 16.8 |      |    |    |    |    |    |    |    |    |
| In-house PCR RdRP   | 21.9 | 18.3 |      |    |    |    |    |    |    |    |    |
| Spira               |      |      | 21.6 | 16.8 | 17.7 | 18.8 |      |    |    |    |    |
| Nasopharynx         |      |      | 27.9 | 24.9 | 25.6 | 27.6 |      |    |    |    |    |
| Virus Culture       |      |      |      |    |    |    |    |    |    |    |    |
| Nasopharynx         |      |      | Positive |    |    |    |    |    |    |    |    |
| Spira               |      |      | Positive | Positive |    |    |    |    |    |    |    |

Reported are the Ct-values of the various SARS-CoV-2 PCR assays used and results (positive or negative) of the virus cultures.

*GISAID number: hCov-19/Netherlands/ZH-EMC-938 **GISAID number: hCov-19/Netherlands/ZH-EMC-939.

The full-length genome of this SARS-CoV-2 variant was infectious (Table 1). Using virus culture, we confirmed that this SARS-CoV-2 variant was recovered using amplicon-based Nanopore sequencing. No discrepancies between the genome sequence and no discrepancies in Ct-values of the E-gene and ORF1ab were noted (Table 1). The full-length genome of this SARS-CoV-2 variant was infectious (Table 1). Considering the importance of genomic SARS-CoV-2 surveillance to provide and maintain reliable diagnostics. By comparing the sequence of the SARS-CoV-2 variant with diminished amplification in the ORF1ab target to other SARS-CoV-2 sequences generated in our laboratory, we were able to identify 5 unique mutations which may have caused this amplification problem: C11450A (nsp10) C14178T (RdRp), G15006T (RdRp), G18394T (Hel), and G20995T (Hel) (Supplemental data Fig. 1).

This case showed diminished amplification in a commercial dual-target SARS-CoV-2 assay. Moreover, this case highlights the importance and urgency of genomic SARS-CoV-2 surveillance to provide and maintain reliable diagnostics. By comparing the sequence of the SARS-CoV-2 variant with diminished amplification in the ORF1ab target to other SARS-CoV-2 sequences generated in our laboratory, we were able to identify 5 unique mutations which may have caused this amplification problem: C11450A (nsp10) C14178T (RdRp), G15006T (RdRp), G18394T (Hel), and G20995T (Hel) (Supplemental data Fig. 1). Contact with the manufacturer did not result in the release of the primer and probe sequences used for the Cobas® dual-target SARS-CoV-2 assay.

Usually, the sequences of primers and probes from commercially available PCR assays are considered proprietary company information and will not be disclosed to customers. However, diagnostics companies have the obligation to perform active post-market surveillance to demonstrate that the assay continues to be “fit-for-purpose”. The EU in vitro diagnostic medical devices regulation that will take effect in May 2022 limits the use of laboratory developed tests. Especially for emerging pathogens that are prone to a high level of genetic variation this could increase the risk of missing information on primer-probe mismatches unless post-market surveillance and transparency to customers is enhanced. The number of variants jeopardizing diagnostic results is currently unclear as there is no systematic reporting system. Only estimations on currently available SARS-CoV-2 genome data can be made. Vogel et al. analysed almost 1,000 SARS-CoV-2 genomes and reported 12 primer-probe mismatches in at least two of the genomes (Vogels et al., 2020). Although in this analysis the RdRp reverse primer seemed potentially problematic, case reports also mention variants with failure of the E-gene and N-gene (Supplemental data Table 1) (Artesi et al., 2020; Li et al., 2020). Additionally, the S-gene target is failing among the widely spread B.1.1.7 alpha variant (Public Health England, 2020).

Recent publicly available primer check tools became available which check for mismatches. However, these platforms are also depending on open data and sharing of the primer sequences (Primer-Check, 2021). Current, genomic SARS-CoV-2 surveillances mostly focuses on mutations in the spike glycoprotein but should also include all primer and probe targeting areas to maintain reliable PCR detection of SARS-CoV-2. Furthermore, Ct-values should be combined with available SARS-CoV-2 data to identify target failures in publicly available data.

Reporting correct Ct-values of the SARS-CoV-2 PCR is of importance for infection prevention and control practices. As there is a clear correlation between viral load, which correlates with Ct-values, and shedding of infectious virus in COVID-19 patients. Ct-values are used to downsparse or stop SARS-CoV-2 infection prevention and control measures in hospitalized COVID-19 patients (van Kampen et al., 2021;
Therefore, we could highly recommend the use of dual-target PCR test in daily practice.

In conclusion, we describe a SARS-CoV-2 variant with diminished amplification of the ORF1ab target in the Cobas® dual-target SARS-CoV-2 assay, highlighting the importance of surveillance of genomic regions used in molecular diagnostics and the importance of the public release of target regions used. In addition, this case underpins the importance of using dual-targets in molecular diagnostic assays to limit the chance of false-negative results due to primer and/or probe mismatches.

Data availability

Sequence data is published on GISAID and also available on request.

Declaration of Competing Interest

Sequencing was funded by ZonMW (grant agreement no: 10150062010005).

SP: received financial support from Gilead Sciences outside of the submitted work.

RM; RS; MK; JW; PM; BOM; DN; JvV; MS; SvB; Jvk: reported no conflict of interest.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jviromet.2021.114397.

References

Artesi, M., Bontems, S., Gobbels, P., et al., 2020. A recurrent mutation at position 26340 of SARS-CoV-2 is associated with failure of the E gene quantitative reverse transcription-PCR utilized in a commercial dual-target diagnostic assay. J. Clin. Microbiol. 58.

Bullard, J., Dust, K., Funk, D., et al., 2020. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin. Infect. Dis. 71, 2663–2666.

Corman, V.M., Landt, O., Kaiser, M., et al., 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25.

Duchene, S., Featherstone, L., Hartiopoulou-Sinanidou, M., Rambaut, A., Lemey, P., Baele, G., 2020. Temporal signal and the phylogenetic threshold of SARS-CoV-2. Virus Evol. 6.

Iglói, Z., Leven, M., Abdel-Karem Abou-Nouar, Z., et al., 2020. Comparison of commercial real-time reverse transcription PCR assays for the detection of SARS-CoV-2. J. Clin. Virol. 129, 104510.

Li, Z., Li, Y., Chen, L., et al., 2020. A confirmed case of SARS-CoV-2 pneumonia with routine RT-PCR negative and virus variation in Guangzhou, China. Clin. Infect. Dis. Primer Check. at https://viroscience-emc.shinyapps.io/primer-check/.

Public Health England, 2020. Investigation of Novel SARS-CoV-2 Variant: Variant of Concern 202012/01, Technical Briefing 3. Public Health England, London, United Kingdom. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950823/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3_-_England.pdf.

van Kampen, J.J.A., van de Vijver, D., Fraaij, P.L.A., et al., 2021. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 12, 267.

Vogels, C.B.F., Brito, A.F., Wylie, A.L., et al., 2020. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nat. Microbiol. 5, 1299–1305.

Wölfel, R., Corman, V.M., Guggemos, W., et al., 2020. Virological assessment of hospitalized patients with COVID-19. Nature 581, 465–469.